US$3.06-0.3%11月13日 收盘
数据截至2026年9月30日，来自2026年11月9日提交的10-Q
Just reported
From Whitehawk Therapeutics, Inc.'s results release of 2026年11月9日; its quarterly report has since been filed.
Actual
US$0.00
Guided
—
No guide given
Actual
-US$0.23
Guided
—
No guide given
Actual
-US$22.9M
Guided
—
No guide given
| 指标 | 截至该日的 3 个月2026年9月30日 | 截至该日的 3 个月2025年9月30日 | 变动 |
|---|---|---|---|
| 营业收入合计 | US$0.00 | US$0.00 | — |
| 利润 | -US$21.2M | -US$17.7M | -19.51% |
| 每股收益 | -US$0.23 | -US$0.26 | +11.54% |
| 自由现金流 | -US$19.7M | -US$15.4M | -27.95% |
这些是单季度数字，不是滚动一年——本站其他地方的数字覆盖十二个月，会大得多。季节性业务在两者之间摆动很大：ServiceNow 在十二月季度赚 20 亿美元自由现金流，在六月季度只有 5 亿。
对比对象是去年同一季度，而不是分析师预测。要说“超预期”或“不及预期”需要一致预期数据，那是我们没有的授权数据——而搞错它比不提更糟。
Whitehawk Therapeutics, Inc. reported on 2026年11月9日. We are fetching the call transcript; its summary follows once the transcript is in.
“We continue to dose escalate patients in our Phase 1 programs for HWK-007 and HWK-016 and remain on track to report initial data in the first half of 2027,”
逐字引自公告，且只在文件将其归于具名人士时才展示。
公告在开盘前或收盘后发布，因此区间从公告日前一个交易日的收盘价到公告日之后那个交易日的收盘价——无论哪种情况，反应都包含在内。
Whitehawk Therapeutics is a clinical-stage oncology therapeutics company applying advanced technologies to established tumor biology to efficiently develop improved antibody drug conjugate (ADC) cancer treatments. Whitehawk's portfolio includes HWK-007, HWK-016 and HWK-206, ADCs engineered to overcome the limitations of first-generation predecessors to deliver a meaningful impact for patients with difficult-to-treat cancers. These assets are in-licensed from WuXi Biologics under an exclusive development and global commercialization PRESS RELEASE agreement. Whitehawk's underlying ADC platform leverages CPT113 as the core linker-payload technology, enhanced with its proprietary Carbon Bridge Cysteine Re-pairing (CBCR) bioconjugation process to support improved stability and therapeutic index. More information on the Company is available at www.whitehawktx.com and connect with us on LinkedIn. Any references to the Company's website or other online resources are provided solely for convenience and are not incorporated by reference into this press release. Investors should rely only on the information contained in this press release and the Company's filings with the Securities and Exchange Commission.
公司自己的描述，取自公告末尾。
引述和公司简介来自 Whitehawk Therapeutics, Inc. 于 2026年11月9日 提交的第 2.02 项 8-K 文件；表格根据其季度报告编制。 在 EDGAR 上阅读公告 股价已按拆股和分红复权。
Set against the company's own guidance and the same quarter a year earlier, not analysts' estimates, which we do not hold. Adjusted figures are the company's own non-GAAP measures, as stated in the release.